Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Animal Models

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Animal Model: AKT1 KO
Preparation Type: Genetic Preparations
DA-related behavior: Normal activity in open field
Gating: No baseline PPI in males, baseline PPI deficit in females (Chen; Emamian did not find PPI deficit in either sex at baseline); PPI deficit caused by amphetamine
Cognitive behavior: No impairment in spatial learning
Response to APD: Antipsychotics did not normalize PPI in females, but GSK inhibitors did
Citations: Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet . 2004 Feb ; 36(2):131-7. Abstract

November 27, 2015
SRF News
SRF Comments
Text Size
Reset Text Size

Check out our most recent webinar, How Can Schizotypy Inform Schizophrenia Research?.
Copyright © 2005- 2015 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright